Skip to content
RUO · Failed Phase 3Tight Junction✓ Free to read

Larazotide

Also called AT-1001

A gut peptide built for celiac disease that failed its big trial, so its program was shut down.

Updated 03 May 2026Read 3 minBacked by 60 studies
The quick version
What it is
An oral peptide that tightens the gaps between gut cells
Is it FDA-approved?
No, its big trial failed in 2022 and the maker quit
How strong is the proof?
Weak now: early studies looked okay, the final one missed
How you take it
By mouth, as a capsule
Typical result
The deciding trial did not beat placebo
Biggest catch
Development is paused; the science said it did not work well enough

Any word with a dotted underline is a science word — tap it for a plain-English meaning.

In plain words.

Larazotide is a capsule, not a shot. That is unusual for a , since most get torn apart in the stomach. You may see it called AT-1001.

Your gut lining has tiny gaps between its cells. These are called tight junctions. Larazotide is meant to tighten those gaps, like closing little gates. The goal was to keep gluten bits from leaking through in people with celiac disease.

It is not . Its big final trial failed. The company that made it stopped working on it.

What people use it for.

It was built for celiac disease. The idea was to use it on top of a gluten-free diet, to help people who still feel sick from tiny bits of gluten.

It is also sold online as a "leaky gut" fix. That use has zero solid human proof. Do not buy it for that.

Does it actually work?

Early on, it looked hopeful. A mid-stage study in 342 people showed fewer celiac symptoms than placebo.

Then came the deciding test. The , called CeDLara, missed its main goal in 2022. It did not work well enough. The maker, 9 Meters Biopharma, shut the program down.

That failure is the whole story. When the biggest, most careful test misses, that should change your mind. For "leaky gut," there is no controlled human data at all.

what you’ve probably heard.

The claims floating around online, and how true they actually are.

It's the leaky gut cure that finally fixes your gut.

no

It is pushed hard online for "leaky gut," but there is no controlled human data for that use at all. It was built for celiac, not the supplement aisle.

Take it and you can eat gluten again.

myth

Never the plan. The most it was ever meant to do is blunt the hit from tiny accidental gluten on top of a strict gluten-free diet. It is not a license to eat bread.

It works for celiac, the studies showed it.

not quite

A mid-stage study in 342 people looked promising. Then the deciding phase 3, CeDLara, missed its main goal in 2022 and the maker shut the whole program down.

It's a pill, so the cheap research powder is easy to take.

not quite

Larazotide only works if it survives your stomach. The trial capsules had a special acid-proof coating. Raw research powder without that coating gets broken down before it can act, so it is basically useless.

How you take it.

It is taken by mouth as a capsule. In the celiac studies it was used along with a strict gluten-free diet.

There is no version to follow anymore. Note that this is an oral . Your gut juices break peptides down fast. So raw research powder is hard to dose by mouth without a special coating.

What to watch out for.

Larazotide was generally well tolerated in the trials. The bigger issue is not side effects. It is that it did not pass its key test.

The real warning is about how it is sold. It is widely pushed online as a "leaky gut" supplement. That use has no controlled human data behind it.

If you have real celiac disease and still feel sick on a strict diet, talk to a gut doctor (a gastroenterologist). We are not your doctor.

Where people get it.

Here are the lanes, safest to riskiest.

  • Brand. None. The phase 3 failed in 2022 and the maker exited.
  • . A few pharmacies still make capsules, about $200–$400 a month. The legal footing is weak, since there is no approved use.
  • Research-only (). Cheap raw powder, about $60–$150 a month. But it is an oral , so it is hard to dose right without an enteric (acid-proof) coating.
  • . Overseas raw. Oral powder with no coating is basically useless, so this rarely makes sense.

Our honest take.

For "leaky gut," skip it. There is no controlled human proof for that, full stop.

For biopsy-confirmed celiac with stubborn symptoms on a strict gluten-free diet, it is a maybe. But only with a gut doctor leading, and only with the failed phase 3 result right in front of you.

We would not pay clinic prices for a drug whose big trial missed. That is the honest read.

The studies behind this.

We read the research so you don't have to. Here's where the facts on this page come from.

  1. 01Yang X, et al. Targeting endothelial tight junctions to predict and protect thoracic aortic aneurysm and dissection. European heart journal. 2023;44(14):1248-1261. PMID: 36638776.
  2. 02Troisi J, et al. The Therapeutic use of the Zonulin Inhibitor AT-1001 (Larazotide) for a Variety of Acute and Chronic Inflammatory Diseases. Current medicinal chemistry. 2021;28(28):5788-5807. PMID: 33397225.
  3. 03Tajik N, et al. Targeting zonulin and intestinal epithelial barrier function to prevent onset of arthritis. Nature communications. 2020;11(1):1995. PMID: 32332732.
  4. 04Veres-Székely A, et al. Zonulin as a Potential Therapeutic Target in Microbiota-Gut-Brain Axis Disorders: Encouraging Results and Emerging Questions. International journal of molecular sciences. 2023;24(8). PMID: 37108711.
  5. 05Damianos JA, et al. Coeliac disease and the intestinal barrier: mechanisms of disruption and strategies for restoration. Gut. 2026;75(4):826-838. PMID: 40579122.
  6. 06Huang YC, et al. Preventive effects of Larazotide acetate (AT-1001) on non-alcoholic fatty liver diseases (NAFLD) in a mouse model. Pediatrics and neonatology. 2026;67(1):84-88. PMID: 40562584.
  7. 07Cippitelli A, et al. AT-1001: a high-affinity α3β4 nAChR ligand with novel nicotine-suppressive pharmacology. British journal of pharmacology. 2015;172(7):1834-45. PMID: 25440006.
  8. 08Hoilat GJ, et al. Larazotide acetate for treatment of celiac disease: A systematic review and meta-analysis of randomized controlled trials. Clinics and research in hepatology and gastroenterology. 2022;46(1):101782. PMID: 34339872.
  9. 09Tuan EW, et al. AT-1001 Is a Partial Agonist with High Affinity and Selectivity at Human and Rat α3β4 Nicotinic Cholinergic Receptors. Molecular pharmacology. 2015;88(4):640-9. PMID: 26162864.
  10. 10Zaveri NT, et al. Functional characterization of AT-1001, an α3β4 nicotinic acetylcholine receptor ligand, at human α3β4 and α4β2 nAChR. Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco. 2015;17(3):361-7. PMID: 25180076.
  11. 11Serena G, et al. Nondietary Therapies for Celiac Disease. Gastroenterology clinics of North America. 2019;48(1):145-163. PMID: 30711207.
  12. 12Dipasquale V, et al. New Therapeutic Challenges in Pediatric Gastroenterology: A Narrative Review. Healthcare (Basel, Switzerland). 2025;13(8). PMID: 40281872.
  13. 13Yonker LM, et al. Viral spike antigen clearance and augmented recovery in children with post-COVID multisystem inflammatory syndrome treated with larazotide. Science translational medicine. 2025;17(809):eadu4284. PMID: 40737433.
  14. 14Yu F, et al. Antibacterial hyaluronic acid hydrogel with sustained release of larazotide as effective colitis treatment. Journal of controlled release : official journal of the Controlled Release Society. 2025;387:114205. PMID: 40915363.
  15. 15Slifer ZM, et al. Larazotide acetate: a pharmacological peptide approach to tight junction regulation. American journal of physiology. Gastrointestinal and liver physiology. 2021;320(6):G983-G989. PMID: 33881350.
  16. 16Veeraraghavan G, et al. Celiac disease 2015 update: new therapies. Expert review of gastroenterology & hepatology. 2015;9(7):913-27. PMID: 25864708.
  17. 17Khaleghi S, et al. The potential utility of tight junction regulation in celiac disease: focus on larazotide acetate. Therapeutic advances in gastroenterology. 2016;9(1):37-49. PMID: 26770266.
  18. 18Freeman HJ. Emerging drugs for celiac disease. Expert opinion on emerging drugs. 2015;20(1):129-35. PMID: 25494908.
  19. 19Glinka DM, et al. The PAR2 Antagonist Larazotide Can Mitigate Acute Histamine-Stimulated Epithelial Barrier Disruption in Keratinocytes: A Potential Adjunct Treatment for Atopic Dermatitis. JID innovations : skin science from molecules to population health. 2025;5(4):100369. PMID: 40330848.
  20. 20Yoosuf S, et al. Evolving Therapy for Celiac Disease. Frontiers in pediatrics. 2019;7:193. PMID: 31157194.
  21. 21Girbal-González M, et al. Is There a Future Without Gluten Restrictions for Celiac Patients? Update on Current Treatments. Nutrients. 2025;17(18). PMID: 41010485.
  22. 22Alhassan E, et al. Novel Nondietary Therapies for Celiac Disease. Cellular and molecular gastroenterology and hepatology. 2019;8(3):335-345. PMID: 31146067.
  23. 23Khroyan TV, et al. High affinity α3β4 nicotinic acetylcholine receptor ligands AT-1001 and AT-1012 attenuate cocaine-induced conditioned place preference and behavioral sensitization in mice. Biochemical pharmacology. 2015;97(4):531-541. PMID: 26256075.
  24. 24McCarville JL, et al. Pharmacological approaches in celiac disease. Current opinion in pharmacology. 2015;25:7-12. PMID: 26414923.
  25. 25Toll L, et al. AT-1001: a high affinity and selective α3β4 nicotinic acetylcholine receptor antagonist blocks nicotine self-administration in rats. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2012;37(6):1367-76. PMID: 22278092.
  26. 26Cardoso-Silva D, et al. Intestinal Barrier Function in Gluten-Related Disorders. Nutrients. 2019;11(10). PMID: 31581491.
  27. 27Cippitelli A, et al. Pharmacological stress is required for the anti-alcohol effect of the α3β4* nAChR partial agonist AT-1001. Neuropharmacology. 2015;93:229-36. PMID: 25689019.
  28. 28Gopalakrishnan S, et al. Larazotide acetate promotes tight junction assembly in epithelial cells. Peptides. 2012;35(1):95-101. PMID: 22401910.
  29. 29Slifer ZM, et al. Larazotide acetate induces recovery of ischemia-injured porcine jejunum via repair of tight junctions. PloS one. 2021;16(4):e0250165. PMID: 33886649.
  30. 30Gopalakrishnan S, et al. Larazotide acetate regulates epithelial tight junctions in vitro and in vivo. Peptides. 2012;35(1):86-94. PMID: 22401908.
  31. 31Yuan M, et al. The α3β4 nAChR partial agonist AT-1001 attenuates stress-induced reinstatement of nicotine seeking in a rat model of relapse and induces minimal withdrawal in dependent rats. Behavioural brain research. 2017;333:251-257. PMID: 28693859.
  32. 32Valitutti F, et al. Breaking Down Barriers: How Understanding Celiac Disease Pathogenesis Informed the Development of Novel Treatments. Digestive diseases and sciences. 2019;64(7):1748-1758. PMID: 31076989.
  33. 33Yonker LM, et al. Zonulin Antagonist, Larazotide (AT1001), As an Adjuvant Treatment for Multisystem Inflammatory Syndrome in Children: A Case Series. Critical care explorations. 2022;10(2):e0641. PMID: 35211683.
  34. 34Kelly CP, et al. Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study. Alimentary pharmacology & therapeutics. 2013;37(2):252-62. PMID: 23163616.
  35. 35Szaflarska-Popławska A. Non-dietary methods in the treatment of celiac disease. Przeglad gastroenterologiczny. 2015;10(1):12-7. PMID: 25960809.
  36. 36Leffler DA, et al. Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. Gastroenterology. 2015;148(7):1311-9.e6. PMID: 25683116.
  37. 37Leffler DA, et al. A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge. The American journal of gastroenterology. 2012;107(10):1554-62. PMID: 22825365.
  38. 38Kulkarni A, et al. Current pharmacological approaches and potential future therapies for Celiac disease. European journal of pharmacology. 2021;909:174434. PMID: 34418405.
  39. 39Paterson BM, et al. The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study. Alimentary pharmacology & therapeutics. 2007;26(5):757-66. PMID: 17697209.
  40. 40Karahan D, et al. Ameliorative Effects of Larazotide Acetate on Intestinal Permeability and Bacterial Translocation in Acute Pancreatitis Model in Rats. Digestive diseases and sciences. 2024;69(4):1242-1252. PMID: 38441784.
  41. 41D'heedene M, et al. Celiac disease: Hope for new treatments beyond a gluten-free diet. Clinical nutrition (Edinburgh, Scotland). 2024;43(6):1240-1249. PMID: 38648685.
  42. 42Caio G, et al. Therapeutic options for coeliac disease: What else beyond gluten-free diet?. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 2020;52(2):130-137. PMID: 31831308.
  43. 43Beken S, et al. Negative Effects of Noise on NICU Graduates' Cochlear Functions. Fetal and pediatric pathology. 2021;40(4):295-304. PMID: 31984823.
  44. 44Yonker LM, et al. Multisystem inflammatory syndrome in children is driven by zonulin-dependent loss of gut mucosal barrier. The Journal of clinical investigation. 2021;131(14). PMID: 34032635.
  45. 45Enomoto H, et al. In vivo assessment of a delayed release formulation of larazotide acetate indicated for celiac disease using a porcine model. PloS one. 2021;16(4):e0249179. PMID: 33844694.
  46. 46Kurada S, et al. Current and novel therapeutic strategies in celiac disease. Expert review of clinical pharmacology. 2016;9(9):1211-23. PMID: 27322016.
  47. 47Jauregi-Miguel A. The tight junction and the epithelial barrier in coeliac disease. International review of cell and molecular biology. 2021;358:105-132. PMID: 33707052.
  48. 48Knox HJ, et al. Characterization of Binding Site Interactions and Selectivity Principles in the α3β4 Nicotinic Acetylcholine Receptor. Journal of the American Chemical Society. 2022;144(35):16101-16117. PMID: 36006801.
  49. 49Baldassarre M, et al. Celiac disease: pathogenesis and novel therapeutic strategies. Endocrine, metabolic & immune disorders drug targets. 2008;8(3):152-8. PMID: 18782011.
  50. 50Silverman GJ, et al. Sex-dependent Lupus Blautia (Ruminococcus) gnavus strain induction of zonulin-mediated intestinal permeability and autoimmunity. Frontiers in immunology. 2022;13:897971. PMID: 36032126.
  51. 51Ailioaie LM, et al. Celiac Disease and Targeting the Molecular Mechanisms of Autoimmunity in COVID Pandemic. International journal of molecular sciences. 2022;23(14). PMID: 35887067.
  52. 52Mousavi Maleki MS, et al. Bromelain and ficin proteolytic effects on gliadin cytotoxicity and expression of genes involved in cell-tight junctions in Caco-2 cells. Amino acids. 2023;55(11):1601-1619. PMID: 37803248.
  53. 53Zofková I. [Celiac disease and its relation to bone metabolism]. Casopis lekaru ceskych. 2009;148(6):246-8. PMID: 19642305.
  54. 54Armandi A, et al. Tight junction regulation in celiac disease: role of larazotide acetate. Minerva gastroenterology. 2022;68(1):4-6. PMID: 33793152.
  55. 55Gharpure A, et al. Agonist Selectivity and Ion Permeation in the α3β4 Ganglionic Nicotinic Receptor. Neuron. 2019;104(3):501-511.e6. PMID: 31488329.
  56. 56Fretzen A. Peptide therapeutics for the treatment of gastrointestinal disorders. Bioorganic & medicinal chemistry. 2018;26(10):2863-2872. PMID: 29183663.
  57. 57Di Micco S, et al. In silico Analysis Revealed Potential Anti-SARS-CoV-2 Main Protease Activity by the Zonulin Inhibitor Larazotide Acetate. Frontiers in chemistry. 2021;8:628609. PMID: 33520943.
  58. 58Di Micco S, et al. Peptide Derivatives of the Zonulin Inhibitor Larazotide (AT1001) as Potential Anti SARS-CoV-2: Molecular Modelling, Synthesis and Bioactivity Evaluation. International journal of molecular sciences. 2021;22(17). PMID: 34502335.
  59. 59Pearce SC, et al. Marked differences in tight junction composition and macromolecular permeability among different intestinal cell types. BMC biology. 2018;16(1):19. PMID: 29391007.
  60. 60Arrieta MC, et al. Reducing small intestinal permeability attenuates colitis in the IL10 gene-deficient mouse. Gut. 2009;58(1):41-8. PMID: 18829978.

We're not your doctor, and this isn't medical advice. It's a plain-English summary of what the research says, so you can have a smarter conversation with someone who is.

Keep up with this stuff

Want the rest of the peptide world, in plain English?

New breakdowns, safety updates, and what's actually worth your money. Free. Unsubscribe in one click.